Stathmin expression in metastatic colorectal cancer
| Autor: | Audrey J. Lazenby, Chandrakanth Are, Lynette M. Smith, Michael G. Brattain, Premila D. Leiphrakpam |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Colorectal cancer Stathmin macromolecular substances Adenocarcinoma medicine.disease_cause Metastasis 03 medical and health sciences 0302 clinical medicine Predictive Value of Tests medicine Humans Neoplasm Invasiveness Aged Neoplasm Staging biology Cell growth business.industry General Medicine Middle Aged Prognosis medicine.disease Primary tumor digestive system diseases Survival Rate Oncology Apoptosis 030220 oncology & carcinogenesis Cancer research biology.protein Immunohistochemistry Female 030211 gastroenterology & hepatology Surgery Colorectal Neoplasms Carcinogenesis business |
| Zdroj: | Journal of Surgical Oncology. 123:1764-1772 |
| ISSN: | 1096-9098 0022-4790 |
| Popis: | OBJECTIVES To evaluate the relationship between stathmin expression and clinical outcome in colorectal cancer (CRC). BACKGROUND Stathmin is a phosphoprotein involved in the regulation of microtubule dynamics and integration of intracellular signaling pathways. Stathmin has been implicated in the tumorigenesis of several cancers and is a potential therapeutic target. METHODS Stathmin expression was evaluated in 25 metastatic CRC (mCRC) patients by immunohistochemistry (IHC). Ki67 IHC and TUNEL assay were also evaluated in mCRC for cell proliferation and apoptosis. RESULTS High expression of stathmin was correlated with CRC metastasis (p = .0084), and significantly worse overall survival (OS) in CRC patients (p = .036). There was a significant increase in cell proliferation and a decrease in apoptosis in liver metastasis compared with CRC primary tumors as determined by Ki67 IHC and TUNEL assay (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text